Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the antiproliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori stent comparing to Cypher stent in Japanese population by a single blinded 3:2 randomized trial and met the primary endpoint, non inferiority in TVF. This is the first report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to Cypher Sirolimus Eluting stent in Japanese population. Methods: This is the first multicenter single-blinded, 3:2 randomized clinical trial comparing Nobori and Cypher in 335 patients (Nobori 198 : Cypher 137) in Japan. Patients with single de novo up to two native coronary lesions were treated. The primary endpoint was TVF (cardiac death, MI and TVR) rate at 9 months; late loss (LL) and restenosis rate (RR) at 8 months were major secondary angiographic endpoints, while MACE and stent thrombosis were major secondary safety endpoints. Duration of dual antiplatelet therapy (DAPT) was also recorded for all patients. Results: No significant difference between both patient backgrounds was found. TLR free rate of Nobori was 98.8% at 2years and 98.3% at 3years. (Cypher 96.0% and 95.2%). MACE free rate of Nobori was 94.1% at 2years and 92.9% at 3years. (Cypher 93.7% and 92.0%). TVF free rate of Nobori was 92.1% at 2years and 90.9% at 3years. (Cypher 93.7% and 91.1%). No definite or probable stent thrombosis according to ARC definition were found in both groups. Conclusions: In this first randomized clinical trial of Nobori and Cypher stent in Japanese population, Nobori stent was found non-inferior to Cypher in TVF, the primary endpoint. TLR free rate at 3 years of Nobori tended to be higher than that of Cypher and the differences in TLR free rate between Nobori and Cypher at 2 years and 3years were increased (no statistical significance). MACE and TVF free rate of both stents at three years were comparable. Further long term follow-up up to 5years may suggest longer term safety of Nobori Stent.
Background: "One-stop" hybrid coronary revascularization (HYBRID) with LIMA-LAD bypass grafting and DES implantations in non-LAD lesions is a newer therapy for the treatment of multivessel coronary artery disease. The present study aimed to compare the angiographic patency rates between HYBRID and PCI at mid-term repeat coronary angiogram. Methods: From June 2007 to December 2009, 104 patients underwent HYBRID and 7165 patients underwent PCI with DES implantations at our center. The major inclusion criteria of the study are: 1) triple vessel disease including revascularizable LAD lesion; 2) heart team consensus reached that either HYBRID or PCI could be performed in each individual; 3) no chest pain and MACCE occurred during clinical follow-up. According to these, 102 patients in Hybrid group and 157 patients in PCI group who agrees to take repeat angiogram were enrolled. From October, 2010 to December, 2011, 50 HYBRID patients signed the agreement and underwent angiogram. Among the 157 PCI cases, 50 patients (1:1) are selected for repeat angiography with the use of propensity score matching method. Results: The angiographic follow-up durations were similar the two groups (18 Ϯ 8.03 months vs. 19.3 Ϯ 9.12 months). There are no significant differences in baseline characteristics. There were 50 LIMA grafts and 64 non-LAD target vessels in Hybrid group; the angiographic target vessel patency rate was 89.5%, and the TLR rate was 7.9%. In PCI group, the angiographic target vessel patency rate was 82.7%, and the TLR rate was 20.4%. There was no significant difference in overall patency between the Hybrid group and PCI group (89.5% vs. 82.7%, pϭ0.07), but a significantly higher patency rate of LIMA-LAD graft in Hybrid group vs. that of stented LAD in PCI group (98% vs. 80%, pϭ0.004); and no significant difference in non-LAD target vessel patency between the two groups (82.8% vs. 85.2%, pϭ0.727). Conclusions: Compared to PCI with DES implantations, the treatment of multivessel coronary artery disease with "one-stop" hybrid revascularization demonstrated that the patency rate of LIMA-LAD graft was superior to that of PCI in LAD, and the non-LAD vessel patency rate was similar in two groups.
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Efficacy Background: Calcified lesions have been known as a cause of stent underexpansion which increases the risk of thrombosis and in-stent restenosis. We evaluated a combination therapy using a dual wire balloon with integral nitinol wire after RA for heavily calcified lesions. Methods: 64 consecutive heavily calcified lesions which need rotational atherectomy (RA) for stent implantation were evaluated. 18 lesions without intravascular ultrasound (IVUS) results and 6 lesions with chronic total occlusion were excluded. 22 lesions treated with a combination therapy using a dual wire balloon after RA. The other 18 lesions were treated with RA alone or the combination therapy using the conventional semi-compliant balloon and RA. After RA, the drug eluting stent (DES) was implanted in all cases. Just after RA, the section with smallest luminal cross sectional area (CSA) with an angle of more than 180 degree calcification was identified by IVUS and the following measurements made at the lesion. Angiographic findings were evaluated just after treatment and 11 months after treatment. Results: Baseline patient's characteristics, lesion characteristics calculated by quantitative coronary angiography, therapeutic procedures were not different between 2 groups. Before implantation of DES, a dual wire balloon enabled adequate dilatation with significantly more cracks without major complications. The minimal stent CSA and the stent expansion ratio which calculated the measured minimal stent CSA divided by the minimal stent CSA predicted by the compliance chart, were similar in both groups. However, the symmetrical expansion was significantly accomplished in the dual wire group compared to the other group (mean ratio calculated by dividing the shortest diameter by the longest diameter at the site of the minimal stent CSA was 0.81Ϯ0.06 vs. 0.77Ϯ0.06, Pϭ0.02). Moreover, the angiographic restenosis rate (6.25% vs. 18.2%, Pϭ0.55) and the target vessel revascularization rate (0% vs. 9.1%, Pϭ0.39) at 11 months after treatment were not significantly different in both groups. Conclusions: By using a dual wire balloon after RA, the adequate symmetrical stent expansion and the acceptable mid-term outcomes were accomplished. Background: Transplant coronary artery disease (TCAD) is a major cause of mortality in patients who are status post orthotopic heart transplantation (OHT). Use of systemic everolimus in OHT patients has been shown to reduce the incidence of TCAD. The safety and efficacy of Xience V, a second-generation everolimus-eluting stent (EES), has not been previously studied in OHT patients. Methods: Patients with OHT who had hemodynamically significant CAD (left main Ն50%, or angiographic diameter stenosis Ն70%), and underwent percutaneous coronary intervention (PCI) with EES were included in the study. We examined procedural success rates, in-hospital and one year mortality and myocardial infarction rates. Primary outcome was target lesion revascularization (TLR). Follow up angiograms were performed at 1 year. Quantitative coronary analysis was used for stenosis analysis. Results: PCI was performed in 24 lesions, and 26 denovo EES were placed. One stent was placed into the left main artery, 12 in left anterior descending, 7 in right coronary artery, and 4 in the left circumflex. The average stent length was 15 Ϯ4.9mm and the average stent diameter was 3 Ϯ 0.6mm. Procedural success rate was 100%. All patients had angiographic follow-up (325 Ϯ 128 days). There were no periprocedural, 30-day, or 1 year deaths/ MIs. No stent thrombosis was noted; 1 patient had focal in-stent restenosis. Target vessel revascularization (TVR) rate was 4.1% (1/24), and TLR rate was 3.8% (1/26). Conclusions: EES is associated with a very low incidence of instent stenosis and target lesion revascularization in patients with TCAD. Further studies are needed to determine whether PCI with EES could alter the long term outcome of patients with TCAD. 
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